Mark W. Hahn, Chief Financial Officer at Verona Pharma plc (VRNA), sold 393,160 shares at $2.54 ($992K) on 2023-08-03, disclosed to the SEC on 2023-08-07.
Scheduled sale ($992k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.54 | 117,272 | $298K | 30.0% |
| 2 | $2.54 | 117,272 | $298K | 30.0% |
| 3 | $2.50 | 150,000 | $375K | 37.8% |
| 4 | $2.47 | 8,616 | $21K | 2.1% |
| Total | $2.52 avg | 393,160 | $992K | 100% |
| Filing → |
| VRNA | SELL | 2025-05-29 | $7.5M | — | Filing → |
| VRNA | SELL | 2025-05-05 | $7.0M | — | Filing → |
| VRNA | SELL | 2025-05-01 | $1.6M | — | Filing → |